Filing Flows

Filing Flows › Companies › Indivior Pharmaceuticals › Cash flow

Indivior Pharmaceuticals cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$83.0M in Q3 2026 · $31.0M over twelve months

Operating cash flow$97.0M
Capital spending−$14.0M
Free cash flow+$83.0M
Cash / net income0.7×
Cash conversion cycle288 days

Analysis

In Q3 2026, Indivior Pharmaceuticals generated $97.0M of operating cash flow and spent $14.0M on capital projects, leaving free cash flow of $83.0M. That is $142M more than in Q3 2025 (−$59.0M).

Over the twelve months to Sep 30, 2026, operating cash flow was $96.0M; the largest uses were buybacks ($302M), capital spending ($65.0M), taxes on employees’ shares ($23.0M); besides operations, cash came from net borrowing (+) / repaid (−) ($151M), other financing ($3.0M); the cash balance fell by $142M.

Operating cash flow was $97.0M against net income of $137M — 0.7× profit, less cash than reported earnings, worth checking against working capital. The largest differences: other liabilities −$49.0M, deferred taxes −$17.0M, prepaid and other assets +$15.0M.

Its cash conversion cycle was 288 days (receivables 70 + inventory 270 − payables 52).

Free cash flow

Indivior Pharmaceuticals: free cash flow by quarterIndivior Pharmaceuticals: free cash flow by quarter−$33.0MQ4 2024$70.0MQ1 2025$141MQ2 2025−$59.0MQ3 2025−$245MQ4 2025−$29.0MQ1 2026$222MQ2 2026$83.0MQ3 2026
Operating cash flow less capital spending.
Indivior Pharmaceuticals: operating cash flow against capital spendingIndivior Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$17.0M$16.0MQ4 2024$75.0M$5.0MQ1 2025$158M$17.0MQ2 2025−$39.0M$20.0MQ3 2025−$221M$24.0MQ4 2025−$9.0M$20.0MQ1 2026$229M$7.0MQ2 2026$97.0M$14.0MQ3 2026
Latest (Q3 2026): Operating cash flow $97.0M, Capital spending $14.0M.

Capital allocation, year by year

Indivior Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearIndivior Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $353MFY2021: Capital spending −$4.0M$353MFY2021FY2022: Operating cash flow −$4.0MFY2022: Net borrowing −$3.0MFY2022: Shares issued $2.0MFY2022: Capital spending −$5.0MFY2022: Buybacks −$90.0M$2.0MFY2022FY2023: Operating cash flow −$300MFY2023: Net borrowing −$12.0MFY2023: Shares issued $3.0MFY2023: Capital spending −$8.0MFY2023: Acquisitions −$129MFY2023: Buybacks −$33.0M$3.0MFY2023FY2024: Operating cash flow $36.0MFY2024: Net borrowing $92.0MFY2024: Shares issued $3.0MFY2024: Capital spending −$29.0MFY2024: Buybacks −$173M$131MFY2024FY2025: Operating cash flow −$27.0MFY2025: Net borrowing −$17.0MFY2025: Shares issued $2.0MFY2025: Capital spending −$66.0MFY2025: Buybacks −$11.0M$2.0MFY2025
Over these 5 years operating cash flow totalled $58.0M; the largest uses were operating cash flow ($331M) and buybacks ($307M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$305M
Debt$488M
Net debt$183M
Due within a year$59.0M

Indivior Pharmaceuticals funds itself: free cash flow was $31.0M over the last twelve months, and $305M of cash and investments stands against $488M of debt ($59.0M due within a year, 5.2× covered by cash).

Indivior Pharmaceuticals: debt maturities by year (FY2025)Indivior Pharmaceuticals: debt maturities by year (FY2025)$59.0MYear 1$55.0MYear 2$52.0MYear 3$50.0MYear 4$243MYear 5
Principal due in each year as disclosed in the annual report, against $305M of cash and investments now.

Where the cash came from and went

Indivior Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Indivior Pharmaceuticals: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$97.0MCash drawn (+) / kept (−)−$82.0MCapital spending−$14.0MNot reconciled−$1.0M
Indivior Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Indivior Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q3 2026Buybacks−$302MNet borrowing (+) / repaid (−)$151MCash drawn (+) / kept (−)$142MOperating cash flow$96.0MCapital spending−$65.0MTaxes on employees’ shares−$23.0MOther financing$3.0MNot reconciled−$2.0M

From profit to cash

Indivior Pharmaceuticals: net income to operating cash flow, Q3 2026Indivior Pharmaceuticals: net income to operating cash flow, Q3 2026Net income$137MDepreciation & amortization$1.0MStock-based pay$8.0MDeferred taxes−$17.0MReceivables−$2.0MInventory$1.0MPrepaid and other assets$15.0MOther liabilities−$49.0MOperating cash flow$97.0M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20267027052288
Q2 20267227559288
Q1 20267534393324
Q4 20256621161216
Q3 20257316850191
Q2 20257327384262
Q1 202584338111310

Every quarter

QuarterOperating cash flowCapital spendingBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$97.0M−$14.0M———−$82.0M$83.0M
Q2 2026$229M−$7.0M−$177M——−$48.0M$222M
Q1 2026−$9.0M−$20.0M−$125M$156M—$20.0M−$29.0M
Q4 2025−$221M−$24.0M—−$5.0M—$252M−$245M
Q3 2025−$39.0M−$20.0M—−$4.0M$1.0M$63.0M−$59.0M
Q2 2025$158M−$17.0M—−$4.0M—−$137M$141M
Q1 2025$75.0M−$5.0M−$11.0M−$4.0M$1.0M−$53.0M$70.0M
Q4 2024−$17.0M−$16.0M−$50.0M−$238M—−$32.0M−$33.0M

Indivior Pharmaceuticals: income statement and cash flow

Indivior Pharmaceuticals, Q3 2026: revenue $356M (+13% year over year), operating margin 50.6%. The chart follows the revenue to costs, profit and cash.

Indivior Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.